Dolutegravir + Rlipivirine + GSK1265744
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infections, Human Immunodeficiency Virus and Hepatitis
Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Trial Timeline
Nov 1, 2011 → Feb 1, 2012
NCT ID
NCT01467531About Dolutegravir + Rlipivirine + GSK1265744
Dolutegravir + Rlipivirine + GSK1265744 is a phase 1 stage product being developed by Shionogi for Infections, Human Immunodeficiency Virus and Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01467531. Target conditions include Infections, Human Immunodeficiency Virus and Hepatitis.
What happened to similar drugs?
20 of 20 similar drugs in Infections, Human Immunodeficiency Virus and Hepatitis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01467531 | Phase 1 | Completed |
Competing Products
20 competing products in Infections, Human Immunodeficiency Virus and Hepatitis